In February 2007 a U.S. military helicopter carrying blood to a field hospital was shot down in Iraq, killing all seven crew members, underscoring the logistical peril of moving perishable blood supplies. A $73 million DARPA program now seeks to replace fragile liquid blood with shelf‑stable, dried plasma, platelets and red cells that could be stored for years and fielded by 2029. At the same time, MIT Technology Review has highlighted Chinese startup WeLion New Energy—one of its 2026 “10 Climate Tech Companies to Watch”—for its liquid‑solid hybrid battery cells that promise higher energy density and improved safety over conventional lithium‑ion packs, a claim bolstered by a 2023 Nio EV demonstration that delivered more than 1,000 km of range.
Key Takeaways
- DARPA’s $73 million effort aims to field dried blood products on the battlefield by 2029.
- The program must prove safety and efficacy of synthetic blood alternatives before deployment.
- WeLion’s liquid‑solid hybrid cells claim higher energy density and safety than lithium‑ion, demonstrated in a 2023 Nio pack with >1,000 km range.
- Scaling production and achieving cost parity remain the biggest hurdles for both technologies.
| Metric | Value | Why it matters |
|---|---|---|
| 2007 helicopter incident | 7 crew killed | Illustrates the risk of transporting fresh blood in combat zones. |
| DARPA budget | $73 million | Funds research into drying and stabilizing blood components. |
| WeLion 2023 Nio pack range | >1,000 km | Demonstrates the practical energy density of the hybrid cell design. |
| Target deployment year for dried blood | 2029 | Sets a concrete timeline for field testing and adoption. |
DARPA’s Shelf‑Stable Blood Initiative
The Defense Advanced Research Projects Agency launched a $73 million program to create dried versions of plasma, platelets and red blood cells that can be stored at ambient temperature for extended periods. The effort follows the 2007 helicopter tragedy, which highlighted how a single loss of fresh blood can cripple medical response on the battlefield.
Technical Approach: Drying Plasma, Platelets, and Red Cells
Researchers are exploring lyophilization and spray‑drying techniques to remove water while preserving the functional proteins and membrane integrity essential for oxygen transport and clotting. Early prototypes have shown that reconstituted plasma retains clotting factor activity, and dried platelets can still aggregate under shear stress. The goal is to package each component in sealed, lightweight bags that survive extreme temperatures and vibration.
Timeline and Remaining Hurdles
DARPA plans to field test the dried blood bags in operational environments by 2029. Critical questions remain around sterility, immunogenicity, and the ability to match blood types after rehydration. Regulatory pathways are also unclear, as the products straddle the line between medical device and biologic. The program’s success will hinge on demonstrating that synthetic alternatives are as safe and effective as fresh donations.
WeLion New Energy’s Liquid‑Solid Hybrid Cells
WeLion New Energy, recognized by MIT Technology Review, is developing a hybrid architecture that combines a liquid electrolyte with a solid‑state separator. The design aims to increase energy density while mitigating the thermal runaway risks that plague conventional lithium‑ion packs. In 2023 the company partnered with EV maker Nio to deliver a battery pack that enabled a driving range of more than 1,000 km on a single charge—a benchmark that suggests the hybrid cells can surpass the gravimetric energy of standard lithium‑ion chemistries.
Performance Claims and Production Challenges
The hybrid cells promise higher specific energy and intrinsic safety because the solid separator reduces dendrite formation, a common failure mode in high‑energy batteries. However, scaling the manufacturing process from lab‑scale roll‑to‑roll coating to gigawatt‑level production remains a major obstacle. Cost parity with established lithium‑ion supply chains is also uncertain, as the specialized materials and dual‑phase assembly add complexity.
Why it matters
Both initiatives address a core logistical bottleneck: the need for high‑performance, resilient supplies in austere environments. Shelf‑stable blood could transform combat medicine, disaster relief, and remote healthcare by eliminating the cold‑chain requirement. Meanwhile, higher‑density, safer batteries could accelerate electrification of transportation, maritime, and aerial platforms, reducing reliance on volatile lithium‑ion chemistries and potentially lowering overall system weight. Watching the 2029 DARPA field test and WeLion’s next production milestone will indicate whether these technologies can move from prototype to mainstream adoption.
Frequently asked questions
What is the primary goal of DARPA’s blood‑stabilization program?
The program seeks to develop dried plasma, platelets and red blood cells that can be stored at room temperature for years and deployed quickly on the battlefield, with a target fielding date of 2029.
How does WeLion’s hybrid battery differ from traditional lithium‑ion cells?
WeLion combines a liquid electrolyte with a solid‑state separator, aiming for higher energy density and reduced thermal‑runaway risk compared with conventional lithium‑ion designs.
What real‑world performance has WeLion demonstrated?
In 2023 the company supplied a battery pack for Nio that delivered a driving range exceeding 1,000 km, showcasing the hybrid cell’s high specific energy.
What are the main technical risks for the dried blood project?
Key concerns include maintaining sterility, ensuring full functional recovery of clotting factors and platelets after rehydration, and meeting regulatory safety standards.
When can we expect to see these technologies in commercial use?
DARPA aims for field testing by 2029; commercial rollout will depend on successful validation and regulatory approval. WeLion’s commercial timeline is less defined, but scaling production and achieving cost competitiveness are cited as the next critical steps.
Bottom Line
DARPA’s $73 million push for shelf‑stable blood and WeLion New Energy’s liquid‑solid hybrid batteries each target a fundamental supply‑chain weakness—perishability and safety. While both promise transformative capabilities, they remain at the prototype stage, with field deployment for dried blood slated for 2029 and large‑scale battery production still facing cost and manufacturing hurdles.
Reporting based on: original source.
Comments
Post a Comment